Vivera Files Response Defending Itself Against The SEC’s Recent Threat Of A Civil Suit

NEWPORT BEACH, Calif., Sept. 30, 2022 /PRNewswire/ — Vivera Pharmaceuticals, Inc. (“Vivera”) announces that it has responded to a recent Wells Notice from the Los Angeles Staff of the U.S. Securities and Exchange Commission (“SEC”) that threatens a civil lawsuit against the Company….